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Abstract
Multiple sclerosis (MS) is a neurodegenerative disease in which the immune system recognizes
proteins of the myelin sheath as antigenic, thus initiating an inflammatory reaction in the central
nervous system. This leads to demyelination of the axons, breakdown of the blood-brain barrier,
and lesion formation. Current therapies for the treatment of MS are generally non-specific and
weaken the global immune system, thus making the individual susceptible to opportunistic
infections. Antigenic peptides and their derivatives are becoming more prevalent for investigation
as therapeutic agents for MS because they possess immune-specific characteristics. In addition,
other peptides that target vital components of the inflammatory immune response have also been
developed. Therefore, the objectives of this review are to (a) summarize the immunological basis
for the development of MS, (b) discuss specific and non-specific peptides tested in EAE and in
humans, and (c) briefly address some problems and potential solutions with these novel therapies.
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Multiple sclerosis (MS) is the most common immune-mediated disease of the central
nervous system. It is characterized by severe demyelination, axonal injury, lesion formation
in the brain and spinal cord, blood-brain barrier (BBB) opening, and inflammatory immune
cell infiltration [1]. MS is a very heterogeneous disease with very diverse pathological and
clinical manifestations. Some of the clinical symptoms include loss of balance and
coordination, visual and sensory impairment, fatigue, and cognitive difficulties [2]. The
pathogenesis of the disease is not well understood, and there are a multitude of factors that
may cause the onset of this disease. Genetic factors may play a major role, and it has been
shown that a particular class-II allele of the major histocompatibility complex (MHC) may
increase the risk for developing MS [3, 4]. Other studies have indicated a correlation
between pathogenic infections and the development of the disease. This is believed to be
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caused by a phenomenon known as molecular mimicry or bystander activation [5]. Some
links have been made between various different viruses to MS, such as the Epstein-Barr
virus [6, 7] and varicella zoster virus [8], as well as bacterial pathogens such as chlamydia
pneumonia [9–11]. However, there is no direct evidence of the link between pathogenic
infections and MS. Currently, the most widely accepted hypothesis is that MS is an
autoimmune disease that affects genetically pre-disposed individuals afflicted with an
environmental pathogen [12].
Diagnosis of MS is complicated and unfortunately the majority of the current treatments are
non-specific. The most common diagnostic tool for MS is magnetic resonance imaging
(MRI). MRI has become a very important tool in diagnosis and monitoring of disease
progression and is crucial for devising proper treatment plans. It is used to look for white
matter lesion formation, particularly in the pons and the cerebellum [13], and the
development of “black holes” that are a hallmark of severe demyelination and axonal
damage [14]. There are currently eight FDA-approved therapies for the treatment of MS.
Four forms of IFN-β therapies are being used for treatment, but their mechanism of action
remains unknown [15]. It is believed that they work primarily by inducing an anti-
inflammatory response [16]. Another commonly used therapeutic agent is glatiramer acetate
(Copaxone), which is a polymer made up of a random mixture of four amino acids (alanine,
glutamic acid, lysine, and tyrosine) [17]. The proposed mechanism of action of Copaxone is
the diversion of the T cell response from type-1 (TH1) to type-2 helper (TH2) T cells.
Mitoxantrone is an alternative drug that works primarily by inhibiting the proliferation of
immune cells [16]. A monoclonal antibody (mAb) called natalizumab (Tysabri) is also being
used to treat MS; it binds the α4β1 integrin [18] to inhibit the migration of lymphocytes into
the BBB, thus preventing the infiltration of immune cells into the central nervous systems
(CNS). Fingolimod (Gilenya), which prevents lymphocytes from exiting the lymph nodes
and keeping them at the periphery so they cannot reach the CNS, is the latest FDA-approved
drug [19].
1.2 Cellular Mechanisms and Role of Cytokines
The body has protective mechanisms in the thymus to prevent and eliminate any
autoreactive T cells by a process known as central tolerance [20]. If autoreactive T cells fail
to become tolerant by resident antigen presenting cells (APC) in the thymus, they can escape
to the periphery, thus making the individual susceptible for the development of an
autoimmune disease. However, the body has back-up protective peripheral-tolerance
mechanisms to prevent these autoreactive T cells from proliferating and attacking self-
components [21]. In the case of MS, it is proposed that both the central and peripheral
tolerance mechanisms fail to induce tolerance or anergy to myelin-specific T cells.
Furthermore, under yet unknown conditions, these myelin-reactive T cells can cross the
BBB to enter the CNS via adhesion molecule interactions [22, 23]. Once in the CNS, these T
cells become re-activated by resident APC such as microglia, macrophages, and dendritic
cells (DC) and induce an inflammatory response in the CNS [20, 24]. DC play a crucial but
contradictory role in the body; they are important both for maintaining peripheral tolerance
and inducing an immunogenic response. It has been reported that DC can pick up myelin
proteins and present them to T cells in the periphery [25–27]. DC have a strong presence in
the inflammatory lesions of MS patients [28] and thus are key players in the reactivation of
autoreactive T cells in the CNS [29]. In addition, DC have been implicated in epitope
spreading [30]. The contribution of B cells to the development and progress of MS is not
very clear. However, a phase II clinical trial using rituximab, a monoclonal antibody which
depletes B cells, was beneficial to MS patients, therefore suggesting that B cells have a role
in the pathogenesis of disease [31], and myelin-specific antibodies have been found in the
cerebrospinal fluid (CSF) of MS patients [32].
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In the past, MS was believed to be solely a CD4+ TH1 disease; recently, evidence has
strongly suggested that CD4+ type-17 T cells (TH17) have a key role in its pathogenesis
[33]. The contribution of TH17 and/or TH1 cells to the disease has not been fully elucidated,
but the balance between these two T cell subsets has an important role in determining the
location of the lesions within the brain [24]. MS is traditionally thought to be purely a
CD4+-mediated disease with little appreciation of the contribution of CD8+ T cells. Myelin-
specific CD8+ T cells have been found in greater amounts in the lesions of MS patients but
not healthy individuals [34–36]; this is unlike myelin-specific CD4+ T cells, which are
found in both MS and healthy individuals [37]. In addition, the depletion of CD4+ cells has
no effect on disease progression, but depletion of both CD4+ and CD8+ T cells has
beneficial effects [38]. Like CD4+, CD8+ T cells are activated in the periphery and can cross
the BBB under inflammatory conditions. Activation of CD8+ in the periphery is
accomplished through cross-presentation, which means APC that do not synthesize myelin
proteins can present antigens to CD8+ T cells in the context of the MHC-I molecule [39].
Activation in the CNS occurs via resident APC, and it still remains unclear which types of
APC are involved [24]. CD8+ T cells exert their effector function in the CNS through the
production of soluble inflammatory mediators as well as direct cell lysis [24, 34, 35].
Therefore, contributions from both CD4+ and CD8+ are probably important in the
development and pathogenesis of disease, and the different involvement of both T cells is
proposed to be the reason behind the broad heterogeneity of the disease [24]. Autoreactive T
cells can recognize several proteins of the myelin sheath as antigenic. The most common
antigenic proteins in MS patients are myelin basic protein (MBP); myelin proteolipid protein
(PLP), which makes up 50% of total myelin protein; and myelin oligodendrocyte
glycoprotein (MOG), which is found on the outside of myelin sheath [5]. Identifying these
autoantigens has become important for developing antigen-specific therapies as well as for
induction of the disease in animal models for studying MS.
Currently, the widely accepted model for T-cell activation and induction of an inflammatory
response is the “two-signal” model [40, 41]. The model proposes that two signals, an
antigen-specific and a “danger” signal, must be delivered to T cells by APC such as an
activated or mature DC (mDC). The maturation of an immature DC (iDC) is triggered by the
phagocytosis of an insoluble antigen [42, 43]. Next, the antigen is broken down into small
peptides, processed, and presented by the APC to a T cell via the MHC-II/T cell receptor
(TCR) interaction; this is known as Signal 1. During the maturation process, the phenotype
of DC changes and expresses costimulatory molecules and adhesion molecules on its surface
(Figure 1). The presence of the costimulatory molecules, also known as Signal 2, informs
the T cell of “danger” and, thus, the T cell differentiates into a pro-inflammatory phenotype
to initiate an inflammatory response. One of the most important costimulatory signals is
delivered via the B7/CD28 protein interaction and is a positive or activation signal [44, 45].
This interaction is vital for the activation of T cells in MS and its animal model,
experimental autoimmune encephalomyelitis (EAE). A second pair of costimulatory
molecules that have been shown to have a major role in the development of helper T cells
are the CD40/CD154 (also referred to as CD40/CD40L) receptors [46]. A study in B7-
deficient mice showed that the CD40/CD154 signal can sufficiently deliver the
costimulatory signal in the absence of the B7/CD28 interaction [47]. Inhibitory (negative)
signals can be delivered to T cells to inhibit its activation via the B7/CTLA-4 interaction
[48]. Cell adhesion molecules also function to activate T cells, most notable molecules are
intercellular adhesion molecule-1 (ICAM-1) and leukocyte function-associated antigen-1
(LFA-1) [49]. Another important group of molecules, which play a big role in influencing
the TH1/TH2 balance in MS, are the inducible costimulator (ICOS) molecule and its ligand
(ICOSL) [50]. It has been reported in the EAE model, that the ICOS/ICOSL interaction can
induce mucosal tolerance by upregulating TH2 and regulatory cytokines [51, 52]. Following
the delivery of Signal 1 and 2, a phenomenon known as the immunological synapse (IS)
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must take place to complete the activation of T cells [53, 54]. The formation of the IS
involves the translocation between Signal 1 molecules (TCR/MHC-II-Ag complex) and the
adhesion molecules (ICAM-1/LFA-1 complex). Because it is believed that the formation of
the IS is vital for the activation of T cells, IS could be an important target for developing
therapeutics aimed at suppressing the immune response.
All the immune responses involved in the pathogenesis and treatment of MS are mediated
via a complex network of cytokines. During steady-state conditions (i.e., homeostasis), there
is a balance between pro- and anti-inflammatory cytokines. In MS, inflammatory cytokines
are responsible for the pathogenesis of the disease in the periphery as well as within the
CNS. The function of each cytokine has not been fully elucidated due to the dynamic
network and complex nature of the cytokine milieu. For the development and progression of
disease, the pro-inflammatory cytokines are key players. There are several cytokines
involved in the inflammatory response, particularly TH1 cytokines such as IL-12, IFN-γ,
and TNF-α as well as TH17 cytokines such as IL-23 and IL-17 [24]. The exact contribution
of each of these cytokines remains unclear and difficult to sort out. The involvement of
IL-12 and IFN-γ was established by their heightened expression in the CNS and CSF of MS
patients with increased clinical activity [55]. In addition, the roles of TNF-α and IFN-γ
were determined when peripheral blood mononuclear cells (PBMC) isolated from MS
patients secreted significant amounts of them [56–61]. IL-17 transcripts were found in CNS
lesions of MS patients, thus indicating a major role of IL-17 in disease pathogenesis [33].
Immunotolerance is believed to be maintained by a group of suppressor (TH2) and
regulatory T cells (Treg) that produce anti-inflammatory cytokines such as IL-2, IL-4, and
IL-10 [62]. During the disease state, it has been reported that PBMC isolated from MS
patients secrete no or low amounts of the anti-inflammatory cytokines [62]. Moreover,
during ongoing disease there is a shift towards the production of pro-inflammatory
cytokines. Therefore, a major strategy for treating an inflammatory disease like MS is
shifting the balance towards the production of anti-inflammatory cytokines such as the ones
secreted by Treg and TH2 cells.
1.3 Experimental Autoimmune Encephalomyelitis
The EAE animal model is used to study the underlying disease pathogenesis of MS and
develop new therapies. EAE can be induced either by adoptive transfer of myelin-specific T
cells or by the administration of a CNS homogenate or specific myelin proteins/peptides in
the presence of an adjuvant such as complete Freund’s adjuvant (CFA) [63]. In order to
facilitate EAE induction and produce more reliable and consistent disease, pertussis toxin
can be injected following the CFA/antigen injection [64]. Also, more recently, a new clone
of transgenic mice possessing PLP139-151 specific TCR has been shown to develop
spontaneous EAE [65]. The EAE model mimics MS in several ways such as the
development of multiple CNS lesions, destruction of the myelin sheath, and the breakdown
of the BBB. Similar to MS, various immune cells are involved in the disease pathogenesis.
Macrophages, microglia cells, DC, B-cell antibodies, and both CD4+ and CD8+ have vital
roles in the development of the inflammatory response and tissue destruction [66]. The
model has been very useful in studying the mode of action of four therapies currently on the
market for the treatment of MS such as glatiramer acetate (Copaxone) [67], mitoxantrone
[68], natalizumab (Tysabri) [69], and, most recently, fingolimod (Gilenya) [70–74]. It is
important to recognize the limitations of the animal model as most successes in that model
did not translate to humans [75]. In addition, many of the adverse side effects observed in
clinical trials, from therapies initially tested in EAE, could not have been predicted from the
animal model [76]. No one model of EAE mimics the heterogeneous pathology of MS and,
therefore, more work must be done in order to more closely mimic the human disease.
Nevertheless, EAE played a key role in understanding many pathogenic aspects of the
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disease and led to the development of four important MS therapeutics; thus, its contribution
in the past must not be undermined. For these reasons, the EAE animal model is
continuously being used to test and develop new therapies for MS.
2 PEPTIDE TREATMENTS FOR MS
Most of the current therapies for MS do not regulate specific immune cells and they
normally suppress the general immune response, which leads to many adverse side effects
from opportunistic infections. Thus, there is a need to develop therapeutic agents that
specifically control the myelin-reactive immune response for maintaining host capability to
protect against foreign pathogens provided by the general immune response. Peptides are
excellent specific inhibitors of protein-protein interactions and, therefore, are valuable
specific modulators of protein-mediated signaling of the immune system. In this section,
many of the current myelin-specific peptides being tested for the treatment of MS will be
discussed. In addition, important advances in the development of non-specific peptides that
have efficacy in the EAE animal model will be discussed.
2.1 Antigenic Peptides
Specific immunotherapy (SIT) has been used for about a century to induce tolerance for the
treatment of allergies such as hay fever [77] and, more recently, seasonal allergic rhinitis
[78], asthma [79], bee venom [80], peanuts [81], cow milk [82], and birch pollen [83]. The
strategy behind allergen- or antigen-SIT is to administer the antigenic protein/peptide in a
proper dose to modulate the immune response and reduce the immunogenicity towards a
particular allergen/antigen [84]. The goal of SIT is to induce T cell anergy, activate Treg, or
promote a shift from a TH1 phenotype to TH2 phenotype [85]. Translating this strategy for
inducing tolerance to treat autoimmune diseases has been the focus of many research
groups. In this section, the successes of antigenic-SIT in the MS animal model and
difficulties in applying the technology to humans will be discussed. In addition, some of the
mechanistic aspects of this therapy will be discussed.
Tolerance induction via the mucosal route has been studied extensively in the EAE model.
There are numerous studies showing that oral administration of myelin proteins or peptides
is an effective way for inducing tolerance, by causing either T cell clonal anergy or
induction of the regulatory immune response. It is reported that this depends on the dose of
the administered antigen [86–88]. The attractive aspect of the oral route is that it mimics
naturally induced tolerance to ingested antigens (with the exception of food allergies), in
addition to its ease of administration. Studies reporting suppression of disease with whole
proteins has been reported [89, 90] and, more importantly, there are numerous studies
showing that induction of tolerance to suppress EAE can be achieved using small protein
fragments and peptides. In one study, MBP fragments (1–37, 44–89, and 90–170)
suppressed the disease significantly [91]. The oral administration of guinea pig-MBP68-88
suppressed rat-MBP68-88-induced EAE in Lewis rats [92]. Other reports showed that MBP
and MBP peptide suppressed PLP-induced EAE, suggesting that bystander suppression is
possible via the oral route [93]. Lastly, another study showed that feeding animals with
PLP139-151 peptide induced T-cell clonal anergy and prevented the onset of EAE [94].
Unfortunately, the success in the EAE animal model could not be translated to MS patients.
One phase-III clinical trial conducted to test the efficacy of orally administered bovine-
myelin containing MBP and PLP showed no significant difference between the treatment
and placebo groups (reviewed in ref. [95]). Thus, even though studies conducted in humans
have proven that administration of antigen via the oral route is a safe method, no studies
have reported any significant benefit so far. The other mucosal route used to deliver antigens
is nasal administration. Studies using MBP whole protein [96, 97], MBP peptides [98], and a
mixture of myelin peptides (PLP139-151, MBP1-11, MBP89-101) [99] have induced peripheral
Badawi and Siahaan Page 5













tolerance and prevented the onset of EAE but, similar to the oral route, no significant benefit
in humans has been reported.
Other routes that have been more successful in attenuating MS and EAE were intravenous
(i.v.) and transdermal administration. There have been several reports indicating the
successful suppression of EAE after i.v. administration of MOG (41–60) and MBP peptides
[100] and whole MBP [101, 102]. When the MBP82-98 peptide fragment was tested in MS
patients, it generally reduced anti-MBP antibodies and significantly delayed the progression
of disease in a particular sub-group of MS patients with the HLA haplotype DR2/DR4 [103].
Another study indicated that i.v. administration of MBP85-96, but not intrathecal or
subcutaneous administration, led to undetectable amounts of MBP autoantibodies in the CSF
for several months post-treatment [104]. More recently, transdermal delivery of myelin
antigens has shown some clinical benefit following the success observed in EAE.
MBPAc1-11 [105] and whole MBP [106] delivered transdermally protected mice from
developing EAE. A small study conducted in patients diagnosed with relapsing-remitting
MS was performed to test the immunological modulation caused by a mixture of three
peptides (MBP85-99, MOG35-55, and PLP139-151) via an adhesive skin patch. Myelin-specific
T cell responses were completely eliminated after only four months of treatment [107]. In
addition, there was an up-regulation in the production of IL-10 and a down-regulation of
TGF-β and IFN-γ in the MS patients, indicating a shift towards an immunotolerant state.
These results are promising and may show clinical efficacy if tested on a larger scale. So far,
translating efficacy from the EAE animal model to MS treatment has proven to be a difficult
task. This is probably due to the complexity and heterogeneity of human autoimmune
diseases. Many factors must be considered when trying to apply antigenic-SIT for the
treatment of human autoimmune disease such as dosing amount and frequency, route of
administration, and specificity of antigens administered.
As described previously, the inflammatory response is initiated by a mDC due to exposure
to an insoluble antigen. The uptake and processing of an insoluble antigen leads to the
activation of a DC and the presentation of the antigen in presence of costimulatory
molecules, thus inducing an inflammatory response. The immunological basis for antigenic-
peptide therapy is that when the peptide is given in a soluble state, it binds directly to empty
MHC-II molecules on the surface of iDC [108]. Because iDC do not have surface
costimulatory molecules, the presentation of antigen by the MHC-II on an iDC in the
absence of costimulatory signal(s) causes the naïve T cells to differentiate to Treg cells after
their interactions with antigen-presenting iDC [43]. Activation and proliferation of Treg cells
influences the balance of the immune response to restore tolerance by shifting from an
effector T cell response (TH1) to an immune-suppressor (TH2) or an immune-regulatory
response (Figure 2).
2.2 Altered Peptide Ligands
Altered peptide ligands (APL) are another group of peptides that are proposed to cause
antigen-specific immunosuppression. These are molecules that are similar in sequence to
native peptides with one or more amino acid modification(s) and can bind to MHC-II
molecules and engage with the TCR to alter or inhibit the delivery of signal to the T cell.
Thus, these molecules act as antagonists to produce T cell anergy or as partial agonists to
produce incomplete activation of T cells. Incomplete activation of T cells will cause a shift
from a pro-inflammatory T cell response (TH1 and TH17) to a regulatory/suppressor T cell
response (TH2 and TH3) [109]. APL with sequence modifications in MBP1-9 [110],
MBP87-99 [111, 112], and PLP139-151 [113–117] have been shown to attenuate disease in the
EAE model. In a phase I clinical trial, an APL from MBP83-99 showed a TH2 bias and
produced anti-inflammatory cytokines; the peptide was well-tolerated by the patients in this
trial [118]. However, when this APL was tested in two separate phase II clinical trials, there
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was no significant clinical benefit seen in treated patients [119, 120]. In one of the clinical
trials, there was no difference observed in the small group of treated patients and the study
was terminated due to adverse side effects from the treatment; in addition 3 of 8 patients
experienced exacerbations of disease [119]. In the other clinical trial, hypersensitivity
reactions were also present and no clinical differences between the APL-treated and the
placebo groups were observed, albeit there was a reduction in the number and volume of
gadolinium-enhanced CNS lesions [120].
Glatiramer acetate (Copaxone) is a random polymer of four amino acids (poly(YEAK)n) that
has been shown to modulate the immune response by competing with MBP epitopes for
MHC binding as well as causing TCR antagonism [121]. Therefore, it is the only APL on
the market for the treatment of MS. Following the success of Copaxone, similar molecules
have been developed and tested in the EAE model. A poly(EYYK)4 peptide that was
developed to bind to the MHC-II binding pocket was shown to inhibit EAE in Lewis rats
[122]. Other molecules such as poly(FYAK)n and poly(VWAK)n also ameliorated both
MBP85-99- and PLP139-152-induced EAE in mice [123, 124]. However, one study indicated
that Copaxone has no beneficial effects on disease progression and the risk of developing
relapses; and therefore, its clinical use may be questionable [125]. It should also be noted
that the efficacy observed from these short amino acid polymers in the animal model may
not be translatable to humans.
2.3 Bifunctional Peptide Inhibitors
Our group has developed a novel group of bifunctional peptide inhibitors (BPI), which
target APC and are proposed to selectively inhibit an immunogenic response towards a
specific antigen. BPI molecules are composed of an antigenic peptide covalently linked to
an adhesion peptide [126]. It is proposed that the antigenic peptide fragment of the BPI
molecule binds to MHC-II molecules and the adhesion peptide binds simultaneously to an
adhesion protein on the surface of the APC. The linker is made up of either aminocaproic
acid or polyethylene glycol (PEG) to ensure simultaneous binding of the antigenic peptide
portion as well as the adhesion peptide (LABL) to their respective receptors on the surface
of the APC. The original length of the linker was estimated upon docking of the antigenic
peptide and LABL peptide to X-ray structures of MHC-II [127] and ICAM-1, respectively
[128–130]. As mentioned earlier, a step necessary for the activation of a pro-inflammatory T
cell response is the formation of the immunological synapse, which occurs at the interface of
APC and T cells and is the translocation of Signal 1 and adhesion proteins [40, 41, 53, 54].
The hypothesis is that BPI molecules bind to both MHC-II (Signal 1) and ICAM-1
(adhesion protein) on the surface of APC to tether both molecules and prevent the formation
of the immunological synapse, thus altering the differentiation and proliferation of T cells
from an inflammatory to a regulatory phenotype.
Several BPI molecules consisting of various antigens and adhesion peptides have been
developed for the suppression of autoimmune diseases in animal models. A GAD-BPI
molecule composed of GAD208-217 and LABL peptides suppressed Type-1 diabetes in the
non-obese diabetes mouse model [131]. GAD-BPI significantly suppressed insulitis and
lowered blood glucose levels compared to control. Currently, CII-BPI composed of a
collagen-II antigenic peptide (CII256-270, CII707-721, or CII1237-1249) conjugated to LABL
peptide attenuated clinical signs of rheumatoid arthritis in the collagen-II-induced model
(unpublished data). More importantly, PLP-BPI, composed of PLP139-151 conjugated to
LABL, was the first BPI molecule to suppress EAE and modulate the immune response by
increasing the proliferation of TGF-β-, IL-4-, and IL-10-producing CD4+CD25+ T cells,
indicating a shift towards a suppressor and regulatory immune response [132–134]. Other
studies with PLP-BPI showed that it can also suppress disease when injected three times
(s.c.), or when dosed in a controlled release fashion [135]. Current studies prove that PLP-
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BPI is effective when administered prior to induction of disease, or even after the
appearance of clinical signs. Recently, PLP-cIBR, which contains cIBR7 peptide from the
D1 domain of ICAM-1, was shown to be more potent than the parent PLP-BPI. A new
MOG-BPI molecule composed of MOG38-50 can suppress MOG-induced EAE in the mouse
model. Finally, a multivalent BPI molecule composed of both MOG38-50 and PLP139-151 has
been shown to suppress disease significantly in both MOG38-50- and PLP139-151-induced
EAE. The value of the multivalent BPI molecule is that it can suppress disease regardless of
the inciting antigen as well as attenuate new antigenic responses created by epitope
spreading.
In summary, BPI molecules have excellent efficacy in suppressing EAE and other
autoimmune diseases in animal models. Current studies indicate that BPI molecules down-
regulate the production of pro-inflammatory cytokines and increase the production of
regulatory cytokines. These results suggest that BPI molecules promote a shift towards a
regulatory and suppressor immune response. However, more studies need to be done to
elucidate the mechanisms of action of BPI molecules.
2.4 Other Peptides
A novel group of non-antigen-specific peptide inhibitors that bind to B7 on the surface of T
cells and prevent the delivery of the costimulatory signal are derived from the sequence of
the CD28 costimulatory protein on the surface of APC [44, 45]. The presentation of an
antigen in the absence of a costimulatory signal will lead to T cell anergy, therefore
inhibiting the inflammatory response (Figure 3). Peptides derived from the conserved region
of CD28 containing the motif MYPPPY bind to B7 and have suppressed EAE in B10.PL
mice [136]. A similar but shorter peptide that showed efficacy in prolonging cardiac
allograft rejection [137] was tested in our laboratory, and results indicated significant
suppression of PLP139-151-induced EAE in SJL/J mice (unpublished data).
Another approach to suppressing the immune response is targeting the CD4 molecule on the
surface of CD4+ T cells. CD4+ T cells are known to have a key role in the pathogenesis of
disease and, therefore, preventing their activation would be a valuable target for attenuating
any CD4+-mediated immune response such as in MS. A cyclic peptide complementary to
the CDR3-like region of CD4 [138] and another peptide designed based on the D1-CC′ loop
region [139] were developed and found to suppress EAE effectively. However, it must be
noted that safety will be a major concern when developing molecules that target molecules
like CD4, since the CD4 molecule is important for the general immune defense mechanisms.
Another immunomodulatory peptide known as RDP58 inhibits TH1 cytokines [140] as well
as upregulates heme-oxygenase-1 [141, 142]. It has been shown that heme-oxyhenase-1 has
a protective role in EAE [143, 144]; therefore, when combined with the inhibition of TH1
cytokines, RDP58 significantly lowered the incidence of EAE in Lewis rats [145].
Recently, new peptides have been developed for the treatment of MS by evaluating them in
EAE animal models. First, IIIM1 is a 9-amino acid peptide derived from histone H2A36-44
that possesses anti-inflammatory activity and suppressed MOG- and PLP-induced EAE
[146, 147]. When administered orally, this peptide reduced the production of pro-
inflammatory cytokines such as IL-17, IFN-γ, IL12, and IL-23 and promoted Treg cell
proliferation accompanied by an increase in TGF-β and IL-10 production. Secondly, four
peptides that bind to the first two extracellular loops (ECL1 and ECL2) of the CC
chemokine receptor 5 (CCR5) have been shown to significantly reduce the infiltration of
monocytes and lymphocytes into the spinal cord and attenuated EAE in mice [148]. CCR5
has been shown to contribute significantly to the pathogenesis of disease by its role in the
activation and migration of leukocytes [149]. Peptides targeting CCR5 have a mechanism of
action similar to that of Tysabri, a monoclonal antibody used for the treatment of MS [150].
Badawi and Siahaan Page 8













Thirdly, glucocorticoid-induced leucine zipper- (GILZ) peptides that bind to nuclear factor-
kappa B (NF-κB) can modulate T-cell activation and induce an anti-inflammatory immune
response to suppress the progression of EAE in mice [151]. GILZ peptides were derived
from the binding sequence of GILZ to the p65 subunit of NF-κB [151]. GILZ-peptides
inhibit the function of NF-κB and suppress the activation of inflammatory cytokines [152].
Finally, it has recently been proposed that treatment of MS can be achieved by modulating
toll-like receptors (TLR) because TLR play an integral part in the development of MS and
EAE [153–156]. Gambuzza et al. described different types of TLR that are involved in
progression of MS and EAE and illustrated several peptides that modulate TLR and can
potentially suppress disease [156].
3 SAFETY CONCERNS
A major safety concern involving antigen or antigen-derived therapies is the risk of
developing anaphylaxis, which is a severe hypersensitivity reaction. Two clinical trials with
an APL were terminated due to hypersensitivity reactions that developed in the patients
[119, 120]. An anaphylactic reaction can occur from the initial burst of immune cell
activation and proliferation accompanied by a storm of cytokine release. The generally
accepted mechanism for induction of anaphylaxis is due to the release of inflammatory
mediators that are triggered by cross-linking of IgE molecules bound to FcεRI on mast cells.
This can lead to life-threatening symptoms such as tissue edema, leukocyte recruitment,
excessive mucous production, and bronchoconstriction [157, 158]. Anaphylaxis has been
observed in numerous EAE models after treatment with myelin peptides [159, 160], but
when the peptides were administered in combination with an anti-IgE antibody, onset of
anaphylaxis was inhibited. The route of administering the peptides plays a major role in
mitigating the risk of developing hypersensitivity reactions. It is thought that i.v. injections
have the greatest risk for developing anaphylaxis since the antigen becomes accessible to the
systemic circulation immediately. S.c. and intradermal injections are believed to have a
lower incidence of anaphylaxis, and mucosal administration is the safest [109]. It should be
noted, however that induction of EAE by priming with myelin peptide in the presence of
CFA leads to the production of IgE molecules [161], thus fostering a hypersensitivity
response. This is in contrast to what occurs in MS patients, in which there is production of
IgG antibodies [104]. To prevent side effects, Wraith et al. suggested that antigenic peptides
could be delivered in a fashion similar to the way that allergens are delivered for the
treatment of allergies [84]. In this case, the antigenic peptide should be administered by
gradually increasing the dose to avoid rapid induction of anergy or activation of Treg that
leads to side effects.
4 CONCLUSIONS
MS pathogenesis is very complex, involving many different branches of the immune system,
and still remains to be fully elucidated. Current treatments for MS are generally non-
specific, leading to suppression of the general immune response to fight pathogenic
infections. Therefore, there is a need to develop more antigen-specific treatments that avoid
this general suppression. Recently, antigen-specific treatments such as antigenic peptides,
APL, and bifunctional peptide inhibitors have been very successful in suppressing EAE in
animal models. Unfortunately, many of these successes in animal models have not been yet
translated to humans in treating MS; this is partly due to the generation of hypersensitivity
reactions upon treatment with the antigenic peptides. In addition, the mechanisms of action
of antigenic peptides and their derivatives in suppressing autoimmune diseases such as EAE
and MS are not yet fully understood. Thus, more research needs to be done to elucidate their
mechanisms of action and delineate why these antigenic peptides and their derivatives
induce side effects such as hypersensitivity reactions. It has been shown that the method of
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delivery and dosing schedule could reduce side effects. In the future, studies performed to
develop novel delivery methods and dosing schedules of antigenic peptide therapies will be
carried out to improve the efficacy and safety profiles of peptide therapies for MS.
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1. The immunological basis for the onset of MS is summarized.
2. Specific and non-specific peptides tested in EAE and in humans are discussed.
3. Some problems and potential solutions with these novel therapies are addressed.
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Activation of a T cell inflammatory response. 1) A steady-state APC such as an immature
DC internalizes an insoluble protein antigen. 2) The antigen is then processed and broken
down into immuno-dominant peptides that can be presented by the MHC-II molecule on the
surface of the APC. 3) Internalization and processing of the antigen triggers the activation of
the DC, thus forming a mature DC (mDC). 4) Presentation of the antigen by the mDC in the
context of the MHC-II molecule to the TCR on a naïve T cell is known as Signal 1. 5) mDC
expresses costimulatory molecules which delivers an activation signal to naïve T cells this is
known as Signal 2. 6) The presentation of an antigen in presence of costimulatory signals
triggers the development of a T cell inflammatory response towards that antigen.
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Administration of soluble peptide antigens induces a T cell regulatory immune response.
Soluble peptides can bind directly to empty MHC-II molecules on the surface of iDC
avoiding internalization and processing of the antigen. Presentation of the antigen in absence
of Signal 2 by an iDC leads to an antigen-specific regulatory response.
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Presentation of antigen with Signal 2 blockade causes improper activation of T cells thus
leading to T cell anergy.
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